We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed at $56.89 in the latest trading session, marking a -1.49% move from the prior day. This change lagged the S&P 500's 0.47% loss on the day. Elsewhere, the Dow lost 0.72%, while the tech-heavy Nasdaq lost 5.08%.
Coming into today, shares of the company had lost 12.23% in the past month. In that same time, the Medical sector gained 0.37%, while the S&P 500 gained 5.36%.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$2.18, up 9.17% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $3.2 million, up 1901.88% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$6.37 per share and revenue of $221.15 million. These totals would mark changes of +23.8% and +18359.92%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 4.43% higher. CRISPR Therapeutics AG is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
CRISPR Therapeutics AG (CRSP - Free Report) closed at $56.89 in the latest trading session, marking a -1.49% move from the prior day. This change lagged the S&P 500's 0.47% loss on the day. Elsewhere, the Dow lost 0.72%, while the tech-heavy Nasdaq lost 5.08%.
Coming into today, shares of the company had lost 12.23% in the past month. In that same time, the Medical sector gained 0.37%, while the S&P 500 gained 5.36%.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$2.18, up 9.17% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $3.2 million, up 1901.88% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$6.37 per share and revenue of $221.15 million. These totals would mark changes of +23.8% and +18359.92%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 4.43% higher. CRISPR Therapeutics AG is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 43% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.